Avalyn Pharma Inc. IPO - What You Need to Know

Thinking about jumping into the Avalyn Pharma IPO? Before you put your hard-earned money on the line, let’s break down what this company does in plain English.

Disclaimer: I am an AI, not a financial advisor. IPOs are risky, so please do your own research or talk to a professional before investing.

1. What does this company actually do?

Avalyn Pharma develops inhaled treatments for rare, life-threatening lung diseases. They focus on pulmonary fibrosis, where lung tissue scars permanently, eventually leading to respiratory failure.

Current treatments are pills that travel through your whole body. This often causes stomach issues, leading many patients to stop treatment. Avalyn’s strategy is to turn these proven drugs into inhaled versions. They use a specialized nebulizer to deliver medicine directly to the lungs. This approach aims to put more medicine where it is needed while reducing side effects elsewhere in the body.

2. How do they make money and are they growing?

Avalyn is still in the research phase. They have no sales and do not expect to make money for a long time. They are currently spending heavily on clinical trials and the FDA approval process.

• Financial Health: The company has raised $389 million from institutional investors. However, they are losing money, reporting an $85.2 million loss for 2025. Expenses will likely rise as clinical trials continue, meaning they will keep losing money for the foreseeable future.
• The Pipeline:
  • AP01 (Inhaled Pirfenidone): Their most advanced project, currently in late-stage testing for lung scarring.
  • AP02 (Inhaled Nintedanib): Currently in clinical trials for lung disease.
  • AP03: A future combination inhaler, with testing expected to start in 2026.

3. What should you know about their reporting?

Avalyn is joining the market as an "Emerging Growth Company." This allows them to follow looser reporting rules. They provide less detail on executive pay, skip certain internal audit requirements, and share fewer years of financial history. As a retail investor, you will have less transparency than you would with a larger, established company.

4. What are the main risks?

• The "All or Nothing" Risk: The company’s success depends entirely on getting their drugs approved. If the FDA rejects their data or finds safety issues, the company may have to stop its programs. This would likely cause shareholders to lose most or all of their investment.
• Cash Burn: The company loses money and needs more cash to keep running. They will likely sell more shares later, which reduces your ownership percentage and lowers the value of your stake.
• The Device Factor: Avalyn relies on a specific nebulizer from a partner, PARI Pharma. If this partnership fails or PARI cannot supply enough devices, Avalyn cannot run trials or sell products. Their entire business would effectively stop.

5. The IPO Details

• Ticker: AVLN (Nasdaq)
• Share Structure: The company uses a dual-class structure. You are buying Class A shares, which carry voting rights.
• The "Secret Sauce": Avalyn plans to sell their drugs and the PARI nebulizer as one integrated package.
• Use of Proceeds: They will use the money from this IPO to fund clinical trials for AP01, AP02, and AP03, as well as for general daily operations.

Final Investor Checklist

Before you decide to buy, ask yourself these three questions:

1. Can I handle the volatility? Biotech IPOs are notoriously "swingy." The stock price will likely react violently to any news—good or bad—about their clinical trials.
2. Do I understand the timeline? This is a long-term play. It will be years before they have a product on the market, if they ever do.
3. Am I okay with the risk of total loss? Because they have no revenue, you are essentially betting on the success of their science. If the science fails, the investment could go to zero.

Bottom line: Think of this like betting on a horse race. You are betting that their science will cross the finish line. It can be rewarding if they succeed, but many of these companies struggle. Only invest what you are comfortable losing!